GLSI Share Price | Greenwich LifeSciences, Inc. Stock Analysis & Recommendation

Q: How big is Greenwich LifeSciences, Inc.?

Market Cap: As of Jun 18, Greenwich LifeSciences, Inc. has a market capitalization of 120.72 million, categorized as a Micro Cap.Recent Quarterly Performance: For the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24, the company reported net sales of 0.00 million and a net profit of -16.58 million.Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 2.53 million, while total assets were reported at 4.09 million.

Q: What does Greenwich LifeSciences, Inc. do?

Overview: Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company engaged in developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 120.72 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -2.10 Return on Equity: -1,262.96% Price to Book: 91.99Contact Details: Address: 3992 Bluebonnet Dr, Building 14, STAFFORD TX : 77477 Tel: 1 203 4343290 Website: https://greenwichlifesciences.com

Q: Is Greenwich LifeSciences, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Greenwich LifeSciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, and the weekly Bollinger Bands also indicate a bullish stance. However, the monthly KST is bearish, and the Dow Theory shows a mildly bullish trend on a monthly basis with no trend on a weekly basis. In terms of performance, the stock has returned -18.56% over the past year compared to a 17.14% return for the S&P 500, indicating underperformance, but it has a positive return of 2.76% year-to-date versus the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

265.57 k

Shareholding (Sep 2025)

FII

2.76%

Held by 17 FIIs

DII

92.2%

Held by 5 DIIs

Promoter

0.00%

How big is Greenwich LifeSciences, Inc.?

22-Jun-2025

As of Jun 18, Greenwich LifeSciences, Inc. has a market capitalization of 120.72 million and reported net sales of 0.00 million with a net profit of -16.58 million for the latest four quarters. As of Dec'24, shareholder's funds were 2.53 million and total assets were 4.09 million.

View full answer

What does Greenwich LifeSciences, Inc. do?

22-Jun-2025

Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company focused on developing GP2, an immunotherapy aimed at preventing breast cancer recurrence post-surgery. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $120.72 million.

View full answer

Who are in the management team of Greenwich LifeSciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Greenwich LifeSciences, Inc. includes David McWilliams (Independent Chairman), Snehal Patel (CEO, CFO, Director), F. Joseph Daugherty (Chief Medical Officer, Director), Kenneth Hallock (Independent Director), and Eric Rothe (Independent Director). They oversee the company's strategic direction and operations.

View full answer

Is Greenwich LifeSciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Greenwich LifeSciences, Inc. shows a mildly bullish trend, supported by bullish weekly MACD and moving averages, despite underperforming the S&P 500 over the past year.

View full answer

Compare Greenwich LifeSciences, Inc. with Similar Stocks

Prelude Therapeutics, Inc.XBiotech, Inc.TScan Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 309 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.74

Return on Equity

-891.35%

Price to Book

141.40

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

233.87%

6 Months

126.21%

1 Year

113.01%

2 Years

209.04%

3 Years

32.21%

4 Years

36.97%

5 Years

-29.05%

Greenwich LifeSciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-274.54%

EBIT to Interest (avg)

-10.16

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.10

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.43%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

98.40

EV to EBIT

-7.54

EV to EBITDA

-7.54

EV to Capital Employed

-87.91

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1262.96%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 9 Schemes (5.04%)

Foreign Institutions

Held by 17 Foreign Institutions (2.76%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -55.56% vs -12.50% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-2.70",
          "chgp": "-55.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-2.70",
          "chgp": "-55.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -77.53% vs -14.10% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.00",
          "val2": "-9.30",
          "chgp": "-72.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.80",
          "val2": "-8.90",
          "chgp": "-77.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.20

-2.70

-55.56%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.20

-2.70

-55.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -55.56% vs -12.50% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.00

-9.30

-72.04%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-15.80

-8.90

-77.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -77.53% vs -14.10% in Dec 2023

All Annual Results

Company CV

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

Pharmaceuticals & Biotechnology

Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.

Company Coordinates

Company Details

3992 Bluebonnet Dr, Building 14 , STAFFORD TX : 77477

Tel: 1 203 4343290

https://greenwichlifesciences.com

Registrar Details

Greenwich LifeSciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Greenwich LifeSciences, Inc.?

Watch in Real-Time

What does Greenwich LifeSciences, Inc. do?

Who are in the management team of Greenwich LifeSciences, Inc.?

Is Greenwich LifeSciences, Inc. technically bullish or bearish?

Compare Greenwich LifeSciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Greenwich LifeSciences, Inc.

Company Coordinates